ArticleACS omega2026
Chitosan-Coated Oleuropein Nanoliposomes Enable Dose-Sparing Suppression of Serum Inflammatory Markers in a TNF-α-Induced Vascular Inflammation Model.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vascular inflammation, marked by endothelial dysfunction and overexpression of proinflammatory cytokines such as interleukin-6 (IL-6) and monocyte chemoattractant protein-1 (MCP-1), is a key contributor to atherosclerosis. Oleuropein (Ole), a phenolic compound with proven anti-inflammatory properties, suffers from poor aqueous stability and limited oral bioavailability, constraining its clinical application. To overcome these limitations, we developed and optimized chitosan (CS)-coated liposomes for oral delivery of Ole. Using a Box-Behnken design, the optimized formulation exhibited a particle size of 168.73 ± 3.86 nm, a polydispersity index (PDI) of 0.17 ± 0.01, a moderate negative zeta potential (-22.50 ± 2.39 mV), an encapsulation efficiency of 87.17 ± 0.27%, and a loading capacity of 12.22 ± 0.25%. The CS-coated formulation retained acceptable colloidal stability under refrigerated storage, enabled pH-responsive sustained release governed by Fickian diffusion, and enhanced endothelial nanocarrier uptake in EA.hy926 cells. The formulation was well tolerated in vitro, with cell viability exceeding 90% across a 500-4000 ng/mL concentration range. In a TNF-α-induced murine model of acute vascular inflammation, daily oral administration of CS-Ole-Lip (20 mg/kg) significantly suppressed serum IL-6 by 6.90-fold (
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.